272 related articles for article (PubMed ID: 28698469)
1. Potential of Integrin Inhibitors for Treating Ovarian Cancer: A Literature Review.
Kobayashi M; Sawada K; Kimura T
Cancers (Basel); 2017 Jul; 9(7):. PubMed ID: 28698469
[TBL] [Abstract][Full Text] [Related]
2. Integrin inhibitors as a therapeutic agent for ovarian cancer.
Sawada K; Ohyagi-Hara C; Kimura T; Morishige K
J Oncol; 2012; 2012():915140. PubMed ID: 22235205
[TBL] [Abstract][Full Text] [Related]
3. Integrin-Targeted Peptide- and Peptidomimetic-Drug Conjugates for the Treatment of Tumors.
Arosio D; Manzoni L; Corno C; Perego P
Recent Pat Anticancer Drug Discov; 2017; 12(2):148-168. PubMed ID: 28164756
[TBL] [Abstract][Full Text] [Related]
4. Radiolabeled Cyclic RGD Peptide Bioconjugates as Radiotracers Targeting Multiple Integrins.
Liu S
Bioconjug Chem; 2015 Aug; 26(8):1413-38. PubMed ID: 26193072
[TBL] [Abstract][Full Text] [Related]
5. Drugs targeting integrins for cancer therapy.
Binder M; Trepel M
Expert Opin Drug Discov; 2009 Mar; 4(3):229-41. PubMed ID: 23489123
[TBL] [Abstract][Full Text] [Related]
6. The organometallic ferrocene exhibits amplified anti-tumor activity by targeted delivery via highly selective ligands to αvβ3, αvβ6, or α5β1 integrins.
Ludwig BS; Tomassi S; Di Maro S; Di Leva FS; Benge A; Reichart F; Nieberler M; Kühn FE; Kessler H; Marinelli L; Reuning U; Kossatz S
Biomaterials; 2021 Apr; 271():120754. PubMed ID: 33756215
[TBL] [Abstract][Full Text] [Related]
7. Exploring the Role of RGD-Recognizing Integrins in Cancer.
Nieberler M; Reuning U; Reichart F; Notni J; Wester HJ; Schwaiger M; Weinmüller M; Räder A; Steiger K; Kessler H
Cancers (Basel); 2017 Sep; 9(9):. PubMed ID: 28869579
[TBL] [Abstract][Full Text] [Related]
8. A function blocking anti-mouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth in vivo.
Bhaskar V; Zhang D; Fox M; Seto P; Wong MH; Wales PE; Powers D; Chao DT; Dubridge RB; Ramakrishnan V
J Transl Med; 2007 Nov; 5():61. PubMed ID: 18042290
[TBL] [Abstract][Full Text] [Related]
9. Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism.
Cai W; Chen X
Anticancer Agents Med Chem; 2006 Sep; 6(5):407-28. PubMed ID: 17017851
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent.
Ramakrishnan V; Bhaskar V; Law DA; Wong MH; DuBridge RB; Breinberg D; O'Hara C; Powers DB; Liu G; Grove J; Hevezi P; Cass KM; Watson S; Evangelista F; Powers RA; Finck B; Wills M; Caras I; Fang Y; McDonald D; Johnson D; Murray R; Jeffry U
J Exp Ther Oncol; 2006; 5(4):273-86. PubMed ID: 17024968
[TBL] [Abstract][Full Text] [Related]
11. Arginine-Glycine-Aspartate-Binding Integrins as Therapeutic and Diagnostic Targets.
Sun CC; Qu XJ; Gao ZH
Am J Ther; 2016; 23(1):e198-207. PubMed ID: 24621642
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
